ストックスクリーナーアプリを入手
247.07
3.85%
-9.90
アフターアワーズ：
247.07
前日終値:
$256.97
開ける：
$256.47
24時間の取引高:
662.25K
Relative Volume:
2.33
時価総額：
$26.47B
収益：
$3.32B
当期純損益:
$-860.46M
株価収益率:
-29.70
EPS:
-8.32
ネットキャッシュフロー:
$-1.04B
1週間 パフォーマンス:
-9.10%
1か月 パフォーマンス:
+10.55%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$245.52
$256.52
1週間の範囲:
$240.00
$264.87
52週間の値動き範囲:
$172.67
$287.88
Beone Medicines Ltd Adr Stock (ONC) Company Profile
名前
Beone Medicines Ltd Adr
セクター
電話
13459494123
住所
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
ONC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
247.07 | 26.47B | 3.32B | -860.46M | -1.04B | -8.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.29 | 125.39B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
707.51 | 77.35B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.21 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
244.52 | 31.65B | 2.25B | -278.16M | -42.59M | -2.17 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-03 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-12-03 | 再開されました | Morgan Stanley | Overweight |
| 2024-09-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-02-06 | 再開されました | JP Morgan | Overweight |
| 2023-09-12 | 開始されました | Macquarie | Outperform |
| 2023-08-17 | 開始されました | Jefferies | Buy |
| 2023-07-17 | 開始されました | Citigroup | Buy |
| 2023-06-30 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | 開始されました | Daiwa Securities | Buy |
| 2022-10-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-10-13 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | 再開されました | JP Morgan | Overweight |
| 2022-03-17 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | 開始されました | Deutsche Bank | Buy |
| 2021-10-12 | 開始されました | Bernstein | Outperform |
| 2021-10-06 | アップグレード | CLSA | Underperform → Buy |
| 2021-03-08 | 開始されました | China Renaissance | Buy |
| 2021-03-01 | ダウングレード | CLSA | Outperform → Underperform |
| 2020-11-09 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | ダウングレード | Maxim Group | Buy → Hold |
| 2020-11-06 | ダウングレード | Piper Sandler | Neutral → Underweight |
すべてを表示
Beone Medicines Ltd Adr (ONC) 最新ニュース
Beigene CEO John Oyler sells shares worth $14.6 million - Investing.com
Beigene’s president Wu Xiaobin sells $13.6 million in shares - Investing.com
Beigene chair Wang Xiaodong sells shares worth over $2 million - Investing.com India
Beigene president sells economic interest in RMB shares for $1.16 million - Investing.com India
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer - Benzinga
BOCOMI: BEIGENE (06160.HK) Guides to Positive 2025 Operating Profit; Rating Kept at Buy - AASTOCKS.com
JPMorgan maintains BeiGene stock Overweight rating, $311 target - Investing.com India
Beigene SVP sells $331,375 in American depositary shares By Investing.com - Investing.com South Africa
Beigene SVP sells $331,375 in American depositary shares - Investing.com India
JPMorgan maintains BeiGene stock Overweight rating, $311 target By Investing.com - Investing.com South Africa
BofA lifts BeiGene stock rating, raises target to $320 - Investing.com India
BofA lifts BeiGene stock rating, raises target to $320 By Investing.com - Investing.com South Africa
Beigene directors Julian and Felix Baker sell $190m in shares - Investing.com India
BeiGene gets FDA Orphan Drug Designation for sonrotocla - Investing.com
Guggenheim lifts BeiGene stock target to $348, maintains Buy rating - Investing.com India
Citizens JMP lifts BeiGene stock target to $348 on strong sales By Investing.com - Investing.com South Africa
Citizens JMP lifts BeiGene stock target to $348 on strong sales - Investing.com India
AASTOCKS Financial NewsBeiGene, Ltd. (ONC) - AASTOCKS.com
UBS Lifts BEIGENE (06160.HK) TP to $330, Rating Buy - AASTOCKS.com
BeiGene stock price target raised to $334 at TD Cowen By Investing.com - Investing.com South Africa
BeiGene stock price target raised to $334 at TD Cowen - Investing.com
BeiGene stock target raised to $308 on strong FY results - Investing.com India
BeiGene stock target raised to $308 on strong FY results By Investing.com - Investing.com South Africa
BeiGene beats Q4 expectations, sees strong 2025 revenue growth - Investing.com
BeiGene beats Q4 expectations, sees strong 2025 revenue growth By Investing.com - Investing.com South Africa
Beigene SVP sells shares worth $310,169 By Investing.com - Investing.com South Africa
Beigene SVP sells shares worth $310,169 - Investing.com India
Beigene's global head of R&D sells $1.29m in shares - Investing.com
Beigene, Ltd. (NASDAQ:ONC) COO Xiaobin Wu Sells 21,267 Shares - MarketBeat
BeiGene stock soars to 52-week high of $258.66 amid robust growth - Investing.com India
BeiGene stock soars to 52-week high of $258.66 amid robust growth By Investing.com - Investing.com South Africa
BeiGene’s president sells $12.5 million in company shares - Investing.com India
BeiGene's president sells $12.5 million in company shares - Investing.com
Beigene's Wang Xiaodong sells $9.4 million in shares - Investing.com India
Beigene's Wang Xiaodong sells $9.4 million in shares By Investing.com - Investing.com South Africa
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
CCBI Adds BEIGENE's TP to $179 for Better Fundamentals This Yr - AASTOCKS.com
BEIGENE (06160.HK) Climbs 6% in Early Session, Expects to Achieve Positive Operating Income This Yr - AASTOCKS.com
Beigene director Wang Xiaodong sells $7.37 million in shares - Investing.com
HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com
(NASDAQ:BGNE) Stock Quotes, Forecast and News Summary - Benzinga
FDA approves BeiGene's TEVIMBRA for advanced gastric cancer treatment - Investing.com
With 45% institutional ownership, BeiGene, Ltd. (NASDAQ:BGNE) is a favorite amongst the big guns - Yahoo Finance
Weekly Upgrades and Downgrades - InvestorPlace
BeiGene shares reiterate Buy rating on robust oncology pipeline - Investing.com
Beigene directors sell shares worth $194.2 million - Investing.com
Beigene sees $274 million stock sale by Hillhouse Investment By Investing.com - Investing.com
10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey
Beigene's Wang Xiaodong sells shares worth $9.19 million - Investing.com
BeiGene settles patent litigation, extends BRUKINSA exclusivity - Investing.com
Beone Medicines Ltd Adr (ONC) 財務データ
収益
当期純利益
現金流量
EPS
Beone Medicines Ltd Adr (ONC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| OYLER JOHN | Chief Executive Officer |
Mar 07 '25 |
Sale |
249.13 |
58,590 |
14,596,247 |
0 |
| OYLER JOHN | Chief Executive Officer |
Mar 06 '25 |
Option Exercise |
0.96 |
526,270 |
503,789 |
4,892,056 |
| OYLER JOHN | Chief Executive Officer |
Mar 06 '25 |
Sale |
259.15 |
40,109 |
10,394,329 |
0 |
| Wu Xiaobin | President, COO & GM China |
Mar 05 '25 |
Option Exercise |
126.71 |
51,921 |
6,578,658 |
51,921 |
| Wu Xiaobin | President, COO & GM China |
Mar 05 '25 |
Sale |
261.59 |
51,921 |
13,581,905 |
0 |
1.85%
1.81%
大文字化:
|
ボリューム (24 時間):